TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9128319
Drug: MISO BID
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MISO BID (200 microg two times daily)
Study: 9128319
Drug: RAN (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAN (150 mg twice daily)
Study: 28131706
Drug: Device-managed automatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device-managed automatic therapy for atrial tachycardia or fibrillation (AT/AF)
Study: 28131706
Drug: In-hospital approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital approach for treatment of symptomatic AT/AF
Study: 26780278
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D3 plus 500 mg calcium
Study: 23278367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tenofovir dipivoxil fumarate 150 mg
Study: 23278367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg
Study: 23278367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tenofovir dipivoxil fumarate 600 mg
Study: 23278367
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of tenofovir dipivoxil fumarate 300 mg
Study: 23278367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg with high-fat meal
Study: 23278367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg fasting vs multiple doses
Study: 23278367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg with food
Study: 10832669
Drug: Ribavirin (Rb)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (Rb) 1200 mg/day
Study: 24977293
Drug: Sublingual ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ketamine wafer (25 mg)
Study: 24977293
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (10 mg)
Study: 22731800
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and 25 mg of meperidine
Study: 22731800
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and 20 mg of hyoscine N‐butylbromide
Study: 16513605
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) after 4 months
Study: 16513605
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) after 13 months
Study: 11737007
Drug: OPFA 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPFA 6 g a day for 16 weeks
Study: 9148018
Drug: Vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine + Immunoglobulin (4 ml given simultaneously with the first vaccine injection)
Study: 3118589
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg acemetacin t.i.d. for 1 week
Study: 28522745
Drug: DEG compared
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEG compared to SEG for use of non‐medication aids
Study: 25315663
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (n=91)
Study: 23745991
Drug: Curcumin (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (2.0 grams orally three times per day, 6.0 grams daily)
Study: 9550777
Drug: Adjusted full
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted full intensity oral anticoagulation (target range: 3.0-4.0 INR)
Study: 9550777
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of low dose aspirin and adjusted low intensity oral anticoagulation (target range: 2.0-2.5 INR)
Study: 21500879
Drug: Palmtop computer-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmtop computer-delivered treatment (CDT) for smoking relapse prevention for one additional month
Study: 21500879
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further computer-delivered treatment or assessment (EMA-Only)
Study: 14691684
Drug: Active absorbable
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active absorbable algal calcium (AAA Ca) 900 mg/day
Study: 11240873
Drug: Intravenous pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pethidine (control group)
Study: 8318243
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 0.3 micrograms/kg/hr and fentanyl 25 micrograms/kg
Study: 30518511
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) daily until the morning of colonoscopy
Study: 30518511
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily until the morning of colonoscopy
Study: 19433391
Drug: Nonpegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpegylated liposomal doxorubicin (NLD) 60 mg/m2 every 3 weeks and trastuzumab loading dose 4 mg/kg followed by 2 mg/kg weekly
Study: 17024639
Drug: Hemopure (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemopure (30 g)
Study: 17024639
Drug: Hemopure (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemopure (45 g)
Study: 11393099
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation program (MRP) including physical therapy, nurse-supervised exercise, and discharge planning
Study: 4948417
Drug: Oral streptomycin-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral streptomycin-dependent mutant Shigella vaccines
Study: 31124836
Drug: Alfaxalone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (0.5 mg/kg bolus intravenous injection)
Study: 28814323
Drug: Sarolaner (Simparic™)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarolaner (Simparic™) at 2 mg/kg
Study: 25665908
Drug: Bone-borne rapid
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-borne rapid maxillary expansion (miniscrew-implant-based)
Study: 21348211
Drug: 1 IU
Normalized name: factor VIII 1 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 IU of oxytocin followed by an infusion of 2.5 IU x h(‐1)
Study: 21348211
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 20 IU at a rate of 700 mlU x min(‐1) followed by 10 IU x min(‐1)
Study: 19485969
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 mg tapering to 600 mg or 1200 mg tapering to 800 mg)
Study: 19485969
Drug: Lorazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (6 mg tapering to 4 mg)
Study: 12760978
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg x2)
Study: 11129502
Drug: Chlorambucil therapy
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil therapy starting with 0.8 mg/kg/4 days, increased by 0.1 mg/kg/4 days cycle
Study: 11129502
Drug: Chlorambucil therapy
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil therapy
Study: 2578971
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of half doses of terbutaline (5 mg twice daily) and theophylline (250 mg twice daily)
Study: 2578971
Drug: Theophylline alone
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline alone (500 mg twice daily)
Study: 2578971
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination treatment (theophylline 500 mg twice daily and terbutaline 10 mg twice daily)
Study: 2578971
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination treatment
Study: 26196199
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition (PO) with medium-chain triglyceride (MCT) formula
Study: 27886064
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (1 × 10^10 CFU of multi-species probiotics)
Study: 24452372
Drug: Single-session 90-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session 90-min Acceptance-Based Behavioral Therapy (ABBT) workshop
Study: 22428464
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg aspirin (high HDL group)
Study: 18490496
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate and olmesartan medoxomil (fixed-dose combination)
Study: 18490496
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with amlodipine or olmesartan
Study: 16174115
Drug: Aortic dissection
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic dissection (AD) surgical treatment
Study: 16174115
Drug: Aortic dissection
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic dissection (AD) medical treatment
Study: 11040176
Drug: 6-mercaptopurine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine (1.5 mg x kg(‐1) x day(‐1)) + prednisone (40 mg/day)
Study: 11040176
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + prednisone (40 mg/day)
Study: 30343563
Drug: i-gel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel®
Study: 26871523
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.7-mg
Study: 26871523
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.35-mg
Study: 21484965
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 or 10 mg/kg every 8 weeks
Study: 20133962
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) program, 10-month duration, three 2-hour group sessions per week
Study: 18042509
Drug: Selegiline Transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline Transdermal System (STS) 3 mg/24 h
Study: 18042509
Drug: Selegiline Transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline Transdermal System (STS) 6 mg/24 h
Study: 12498526
Drug: Various pharmacologic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pharmacologic therapies (acetaminophen, traditional NSAIDs, COX-2 inhibitors, intra-articular steroids, viscosupplements, glucosamine, chondroitin sulfate, capsaicin)
Study: 113626
Drug: Primary radiation
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiation treatment
Study: 30789432
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment selection rule based on predicted mean difference in outcomes comparing those with versus without treatment, conditional on covariates.
Study: 30789432
Drug: Treatment selection
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment selection when resources are constrained.
Study: 30789432
Drug: Treatment selection
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment selection when resources are not constrained.
Study: 30789432
Drug: Treatment selection
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment selection in the presence of side effects and costs.
Study: 30789432
Drug: Treatment selection
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment selection to maximize effect heterogeneity.
Study: 28388820
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy and Methotrexate-etanercept
Study: 19879683
Drug: E2/DRSP (17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/DRSP (17beta‐estradiol 1mg plus drospirenone 2 mg daily)
Study: 19879683
Drug: E2/NETA (17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (17beta‐estradiol 1mg plus norethisterone acetate 0.5 mg daily)
Study: 17144496
Drug: Rhino Rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhino Rapid Nasal Dressing with Gel Knit
Study: 14716694
Drug: donepezil+sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil+sertraline (50-200 mg)
Study: 14716694
Drug: donepezil+sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil+sertraline
Study: 9759799
Drug: Theophylline (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (target STC of 10 to 15 mg/L)
Study: 30148973
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (combination of endurance and resistance training)
Study: 29124831
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone acetonide 0.1% oral paste
Study: 29124831
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical triamcinolone acetonide 0.1% and oral methotrexate
Study: 25044085
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical testosterone gel (1% T gel)
Study: 20864808
Drug: Active vaccine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vaccine (DNA prime, recombinant fowlpox virus boost)
Study: 15080407
Drug: Deferiprone 50
Normalized name: deferiprone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone 50 mg/kg
Study: 15080407
Drug: Deferiprone 75
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 75 mg/kg
Study: 11085324
Drug: MDMA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (50 to 150 mg)
Study: 8173687
Drug: Felodipine-Metoprolol 10/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-Metoprolol 10/100 mg
Study: 971343
Drug: Cholestyramine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (16 g/day)
Study: 3781686
Drug: Probucol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (1 g/day)
Study: 3781686
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Probucol + Cholestyramine)
Study: 3235476
Drug: Flosequinan (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (single dose)
Study: 3235476
Drug: Flosequinan (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (chronic treatment)
Study: 15545155
Drug: Co‐amilozide (diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co‐amilozide (diuretic combination)
Study: 10740725
Drug: Y virilin
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y virilin (Treatment Group A)
Study: 10740725
Drug: Placebo (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Treatment Group B)
Study: 29559834
Drug: Oral Ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ibuprofen (OI) for 6 weeks
Study: 27081873
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) [λ=640 nm, SAEF=1.06 J/cm²]
Study: 25623934
Drug: Morphine 1mg
Normalized name: MORPHINE 1MG/ML DEXTROSE 250ML
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 1mg
Study: 22935323
Drug: LAM-EC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM-EC group (received counseling for both LAM and EC with in-advance provision of one packet of EC pills)
Study: 18172020
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to sustained-release bupropion (Level 2)
Study: 18172020
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to sertraline (Level 2)
Study: 18172020
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to extended-release venlafaxine (Level 2)
Study: 18172020
Drug: Continue citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue citalopram and receive augmentation with sustained-release bupropion (Level 2)
Study: 18172020
Drug: Continue citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue citalopram and receive augmentation with buspirone (Level 2)
Study: 14689413
Drug: Single-lumen tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-lumen tube with bronchial blocker
Study: 10983674
Drug: High-dose GIK
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GIK therapy (insulin solution 225 IU, glucose, potassium, and mixed amino acids 11.4 g)
Study: 10983674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mixed amino acids 11.4 g)
Study: 1543675
Drug: 0.1% gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% gentamicin sulphate cream
Study: 4024909
Drug: TTS‐scopolamine (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS‐scopolamine (one patch)
Study: 29808331
Drug: Topical chamomile
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chamomile oleogel
Study: 26848258
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day conivaptan
Study: 26848258
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day conivaptan
Study: 22788574
Drug: Moleca® shoes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moleca® shoes for six months for at least six hours daily
Study: 17297176
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo cream)
Study: 7526468
Drug: Vinorelbine (Navelbine)
Normalized name: vinorelbine Injection [Navelbine]
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (Navelbine) as a single agent
Study: 7526468
Drug: Vinorelbine in
Normalized name: vinorelbine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine in combination with other agents (5-fluorouracil/leucovorin, mitomycin-C, ifosfamide, carboplatin, paclitaxel)
Study: 29676193
Drug: Fidget spinners
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidget spinners (used by 48 children during the initial phase of treatment)
Study: 29676193
Drug: Fidget spinners
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidget spinners (used by 48 children during both phases of treatment)
Study: 28872486
Drug: Divalent iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalent iron (ferrous sulfate) 2 mg/kg/d for 5 months
Study: 28872486
Drug: Trivalent iron
Normalized name: Iron trivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent iron (ferric polymaltose) 2 mg/kg/d for 5 months
Study: 27271310
Drug: Midodrine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (2.5-10 mg)
Study: 27271310
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midodrine and binder
Study: 24638033
Drug: Reading in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading in color with specially prepared books pairing letters with colors; details on dosage and duration not specified.
Study: 24638033
Drug: Reading experience
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading experience questionnaire administered post-intervention; details on dosage and duration not specified.
Study: 20807303
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea (960 mL daily for 6 months)
Study: 9726343
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day)
Study: 24034580
Drug: Buccal placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal placement of 400-mcg misoprostol
Study: 11387284
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mifepristone administered on day LH + 2
Study: 10402385
Drug: HCG administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG administered after endogenous LH surge (Group 2)
Study: 10402385
Drug: HCG administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG administered before endogenous LH surge (Group 3)
Study: 8607570
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 g of syrup)
Study: 321508
Drug: Naftidrofuryl (Praxilene)
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (Praxilene) 300 mg daily for 90 days